Page last updated: 2024-11-11

bis(1,3-dibutylbarbiturate)trimethine oxonol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bis(1,3-dibutylbarbiturate)trimethine oxonol: fluorescent probe for membrane potentials [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

bis(1,3-dibutylbarbituric acid)pentamethine oxonol: a bis-oxonol dye [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6438341
MeSH IDM0149758
PubMed CID22832071
MeSH IDM0149758

Synonyms (27)

Synonym
bis(1,3-dibutylbarbiturate)trimethine oxonol
1,3-dibutyl-5-[(e)-3-(1,3-dibutyl-2,4,6-trioxo-1,3-diazinan-5-yl)prop-2-enylidene]-1,3-diazinane-2,4,6-trione
dibac4
bis(1,3-dibutylbarbituric acid)trimethyne oxonol
di-ba-c4
110425-49-5
diba-c4
2,4,6(1h,3h,5h)-pyrimidinetrione, 1,3-dibutyl-5-(3-(1,3-dibutylhexahydro-2,4,6-trioxo-5-pyrimidinyl)-2-propenylidene)-
dibac4(3)
HY-101892
CS-7987
bis(1,3-dibutylbarbituric acid) trimethine oxonol, >=95% (hplc)
MS-29594
PD078416
AKOS040744062
bis(1,3-dibutylbarbituric acid)pentamethine oxonol
bis-(1,3-dibutylbarbituric acid)pentamethine oxonol
63560-89-4
dibac4(5)
1,3-dibutyl-5-[(2e,4e)-5-(1,3-dibutyl-2,4,6-trioxohexahydropyrimidin-5-yl)penta-2,4-dien-1-ylidene]pyrimidine-2,4,6(1h,3h,5h)-trione
DTXSID50628576
bis-(1,3-dibutylbarbituric acid)pentamethine oxonol (dibac4(5))
neurodyedibac4(5)
1,3-dibutyl-5-[(2e,4e)-5-(1,3-dibutyl-2,4,6-trioxo-1,3-diazinan-5-yl)penta-2,4-dienylidene]-1,3-diazinane-2,4,6-trione
bis-(1,3-dibutylbarbituric acid)pentamethine oxonol(dibac4(5))
2,4,6(1h,3h,5h)-pyrimidinetrione, 5,5'-[(1e,3e)-1,3-pentadien-1-yl-5-ylidene]bis[1,3-dibutyl-
neurodye dibac4(5)

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" PCMBS inhibited F uptake by up to 83% in a dose-response manner."( pH-dependent fluoride transport in intestinal brush border membrane vesicles.
Ganapathy, V; He, H; Isales, CM; Whitford, GM, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (89)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (1.12)18.7374
1990's29 (32.58)18.2507
2000's33 (37.08)29.6817
2010's26 (29.21)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.82 (24.57)
Research Supply Index4.45 (2.92)
Research Growth Index6.28 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews1 (1.18%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other84 (98.82%)84.16%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]